GlaxoSmithKline Share Price (GSK)

1,500.00 +5.80 (+0.39%) delayed: 12:21AM BST
Bid price 1,499.60 Open price 1,496.00
Ask price 1,500.00 Prev close 1,500.00
High price 1,502.20 Spread 0.03%
Low price 1,488.40 Volume 9,571,433

Register now for FREE live GlaxoSmithKline share prices, GlaxoSmithKline stock quotes, charts, trades market news and much much more. Why not upgrade to a premium service and get GlaxoSmithKline Level 2 Data, indepth research tools and investor commentary for GlaxoSmithKline (GSK) and other London Stock Exchange equities.

GlaxoSmithKline Share Price Chart

Advanced Charts >>

Register now for FREE GlaxoSmithKline share price charts

GlaxoSmithKline Share Price Information

Name GlaxoSmithKline Epic GSK
Sector Pharmaceuticals & Biotechnology ISIN GB0009252882
Activites GlaxoSmithKline (GSK) is a world leading research-based pharmaceutical company with a powerful combination of skills and resources that provides a platform for delivering strong growth in today's rapidly changing healthcare environment. Headquartered in the UK and with operations based in the US, the new company is one of the industry leaders, with an estimated seven per cent of the world's pharmaceutical market. GSK also has leadership in four major therapeutic areas - anti-infectives, central nervous system (CNS), respiratory and gastro-intestinal/metabolic. In addition, it is a leader in the important area of vaccines and has a growing portfolio of oncology products. The company also has a Consumer Healthcare portfolio comprising over-the-counter (OTC) medicines, oral care products and nutritional healthcare drinks, all of which are among the market leaders. GSK has over 100,000 employees worldwide. Of these, over 40,000 are in sales and marketing, the largest sales force in the industry. Around 35,000 employees work at 82 manufacturing sites in 37 countries and over 15,000 are in R&D. GSK R&D is based at 24 sites in 11 countries. The company has a leading position in genomics/genetics and new drug discovery technologies. The GSK R&D budget is about £2.8bn/$5bn. Index FTSE 100

GlaxoSmithKline Key Numbers

Latest Share Price (p) 1,500.00 Net Gearing (%) 87.01
Market Capitalisation (£m) 74,766.45 Gross Gearing (%) 93.81
Shares in issue (m) 4,959.30 Debt Ratio 88.30
P/E Ratio 48.01 Debt-to-Equity Ratio 0.50
Total dividends per share (p) 80.00 Assets / Equity Ratio 16.16
Dividend Yield (%) 5.31 Price to book value 21.43
Dividend cover (x) 0.39 ROCE (%) 11.82
Earning per share (p) 31.40 EPS Growth (%) 67.02
52 week high / low 1,724.50 / 1,236.40 DPS Growth (%) 0.00

GlaxoSmithKline Director Deals

Dec.Date Type Director Pos No. of Shares
26/04/2018 BUY Sir Roy Anderson NED 497
26/04/2018 BUY Sir Philip Hampton CH 3,027
26/04/2018 BUY Urs Rohner NED 497
26/04/2018 BUY Manvinder Banga NED 1,989
26/04/2018 BUY Dr Vivienne Cox NED 367

More GlaxoSmithKline Director Deals >>

GlaxoSmithKline Company News

13:20 21/05/2018

GlaxoSmithKline joint venture's HIV treatment approved in Europe

GlaxoSmithKline said a HIV treatment developed by ViiV Healthcare, Janssen and a joint venture with Pfizer and Shionogi was granted marketing approval by the European Commission. The HIV specialist joint venture was granted authorisation for Juluca, which treats HIV type-one infections in adults...

11:02 21/05/2018

ViiV granted EU marketing authorisation for Juluca

RNS Number : 7216O GlaxoSmithKline PLC 21 May 2018       Issued: 21 may 2018, London UK - LSE Announcement   ViiV Healthcare receives EU marketing authorisation for Juluca (dolutegravir/rilpivirine), the first 2-drug regimen, once-daily, single-pill for the...

13:39 15/05/2018

Director/PDMR Shareholding

RNS Number : 1568O GlaxoSmithKline PLC 15 May 2018   GlaxoSmithKline plc   (the   ' Company ') Transaction notification 1. Details of PDMR/person closely associated with them ('PCA') a) Name Mr P Thomson b)...

More GlaxoSmithKline Company News >>

Register now for FREE GlaxoSmithKline company news

GlaxoSmithKline Share Price Discussions

more than 1 year ago

Glaxo trading near low (GSK)

there seems to be some heavy resistance around these level with a lot of potential upside.

more than 1 year ago

Traders Thread - Friday 13th February (GSK)

UK PreMarket Futures FTSE +8 DAX Unch DOW +26 S&P +2 Nasdaq +5 1 Day 2 Day...

more than 1 year ago

Traders Thread - Friday 13th February (GSK)

UK PreMarket Futures FTSE +8 DAX Unch DOW +26 S&P +2 Nasdaq +5 1 Day 2 Day...

Register now for FREE GlaxoSmithKline share price discussions